teclistamab + talquetamab + elranatamab

**Teclistamab + talquetamab + elranatamab** is an investigational triplet combination of three bispecific T-cell engager antibodies for relapsed/refractory multiple myeloma (RRMM). Teclistamab and elranatamab are BCMA x CD3 bispecifics that redirect T cells to lyse BCMA-expressing myeloma cells, while talquetamab is a GPRC5D x CD3 bispecific targeting GPRC5D on myeloma cells and keratinocytes. Developed primarily by Janssen (Johnson & Johnson), this regimen aims to overcome antigen escape by dual- or triple-targeting tumor antigens, showing promising early efficacy in heavily pretreated patients, though specific triplet data is limited and combinations like teclistamab + talquetamab have demonstrated higher ORRs (e.g., 78.9%) and deeper responses than monotherapies in phase 1/2 trials.[1][7][8]